Proton pump inhibitors are an independent risk factor for an increased length of hospital stay in patients with Clostridium difficile infection.

Nachnani, Jagdish S; Bulchandani, Deepti; Allen, Mark J.
Artículo en Inglés | IMSEAR | ID: sea-65605

Documentos relacionados

  1. Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection.
  2. Can prediction scores be used to identify patients at risk of Clostridioides difficile infection?
  3. Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.
  4. The microbial diversity following antibiotic treatment of Clostridioides difficile infection.
  5. Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
  6. Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection.
  7. A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences.
  8. A US-based national surveillance study for the susceptibility and epidemiology of <i>Clostridioides difficile</i> isolates with special reference to ridinilazole: 2020-2021.
  9. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.
  10. In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile.